Maxigen Biotech Inc.

1783

TW0001783009

Personal Products

End-of-day quote Taiwan S.E. Other stock markets 03:30:00 16/07/2024 am IST			5-day change	1st Jan Change
44.75 ^TWD	-1.00%		+1.59%	-7.54%

05/07	Maxigen Biotech Inc. Announces Common Stock Dividend, Payable on August 16, 2024	CI
06/05	Maxigen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Maxigen Biotech Inc. Reports Consolidated Revenue Results for the Month and Year to Date Ended December 2021

January 06, 2022 at 09:18 pm IST

Maxigen Biotech Inc. reported consolidated revenue results for the month and year to date ended December 2021. The company's revenues for December 2021 were approximately TWD 41,072,000 a decrease of 35.68% over the same period in 2020.

The company's revenues for January through December 2021 totaled TWD 511,976,000 an increase of 11.86% compared to the same period in 2020.

Latest news about Maxigen Biotech Inc.

Maxigen Biotech Inc. Announces Common Stock Dividend, Payable on August 16, 2024	05/07	CI
Maxigen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	06/05	CI
Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2023 to December 31, 2023	03/05	CI
Maxigen Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Maxigen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Maxigen Biotech Inc.(TWSE:1783) added to S&P Global BMI Index	18/23/18	CI
Maxigen Biotech Inc. Declares Dividend, Payable on October 12, 2023	23/23/23	CI
Maxigen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	26/23/26	CI
Maxigen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Maxigen Biotech Inc. Announces Cash Dividend for the Period from January 1, 2022 to December 31, 2022	03/23/03	CI
Maxigen Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/23/23	CI
Maxigen Biotech Inc. Announces Executive Changes	22/23/22	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year to Date Ended December 2022	06/23/06	CI
Maxigen Biotech Inc. Announces Resignation of You Wan-How as Financial Officer and Accounting Officer	29/22/29	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year to Date Ended November 2022	06/22/06	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year to Date Ended October 2022	07/22/07	CI
Maxigen Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	25/22/25	CI
Maxigen Biotech Inc. Reports Consolidated Revenue Results for the Month and Year-To-Date Ended September 2022	05/22/05	CI
Maxigen Biotech Inc. Reports Consolidated Revenue Results for the Month and Year-to-Date Ended July 2022	09/22/09	CI
Maxigen Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	03/22/03	CI
Maxigen Biotech Inc. Reports Consolidated Revenues Results for the Month and Year-To-Date Ended June 2022	07/22/07	CI
Maxigen Biotech Inc. Announces Consolidated Revenue Results for the Month and Year to Date Ended May 2022	06/22/06	CI
Maxigen Biotech Inc. Announces Resignation of Lu Min Hsuan as Chief Internal Auditor	13/22/13	CI
Maxigen Biotech Inc. Reports Consolidated Revenue Results for the Month and Year to Date Ended April 2022	06/22/06	CI
Maxigen Biotech Inc. Approves the Appointment of You Wan-How, Manager as Financial Officer and Accounting Officer	03/22/03	CI

Chart Maxigen Biotech Inc.

Duration

Period

More charts

Company Profile

MAXIGEN BIOTECH INC. is a Taiwan-based company principally engaged in the manufacture and sales of biological products, the wholesale of all kinds of medical equipment, medicines, foods, masks, skin care products, as well as the manufacture and sales of chemical materials. The Company operates through two main segments. The Consumer Products segment is mainly engaged in the wholesales of cleansing products, facial care products, medical beauty products and others. The Biomedical Products is mainly involved in the manufacture and sales of Formagraft collagen and ceramic composite material products, Foramic ceramic bone feed materials, Artiaid hyaluronic acid joint injection products, ViscAid ophthalmology viscoelastic agents, as well as SurgiAid wound collagen materials and others.

Sector

Personal Products

Calendar

24/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Cosmetics & Perfumes

	1st Jan change	Capi.
MAXIGEN BIOTECH INC.	-7.54%	122M
L'ORÉAL	-10.96%	233B
KAO CORPORATION	+16.78%	19.7B
GALDERMA GROUP AG	0.00%	19.52B
SHISEIDO COMPANY, LIMITED	+8.00%	11.4B
COTY INC.	-18.44%	8.74B
AMOREPACIFIC CORPORATION	+3.31%	6.66B
PROYA COSMETICS CO.,LTD.	-2.28%	5.28B
NATURA &CO HOLDING S.A.	-7.28%	4B
INTER PARFUMS, INC.	-11.76%	4.07B